ArticleCureus2025
Second-Trimester Induction Abortion Using Two Pretreatment Mifepristone Regimens: A Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Second-trimester abortion is a critical aspect of reproductive healthcare, and reducing the induction-to-expulsion interval (IEI) improves patient outcomes. Mifepristone followed by misoprostol is the standard regimen. This study evaluates whether sequential dosing of mifepristone shortens the IEI compared to a single dose. Methods A randomized controlled trial was conducted at Amrita Institute of Medical Sciences with 54 women between 13 and 20 weeks of gestation. Participants were randomized into two groups: the Mife-1 group received a single 200 mg dose of mifepristone on Day 1, while the Mife-2 group received 200 mg on Days 1 and 2. Misoprostol (600 mcg vaginally, followed by 400 mcg orally every four hours) was administered after 36-48 hours. The primary outcome was IEI; secondary outcomes included prostaglandin requirement and the need for surgical evacuation. Results The Mife-2 group had a significantly shorter IEI (7.93 ± 3.679 hours) compared with the Mife-1 group (10.41 ± 4.263 hours, p = 0.026). Prostaglandin requirement was lower in the Mife-2 group, though not statistically significant (p = 0.087). Fewer participants in the Mife-2 group required surgical evacuation. Conclusions Sequential mifepristone dosing significantly reduces IEI, suggesting improved efficiency in second-trimester abortion. Larger studies are recommended to confirm safety and effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.